Cytosorbents Corp (NASDAQ:CTSO) CFO Kathleen P. Bloch acquired 3,000 shares of the stock in a transaction on Friday, May 10th. The shares were bought at an average cost of $6.49 per share, for a total transaction of $19,470.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
Shares of NASDAQ:CTSO traded up $0.04 on Thursday, hitting $6.90. 900 shares of the company’s stock were exchanged, compared to its average volume of 147,309. The stock has a market cap of $223.88 million, a P/E ratio of -12.40 and a beta of 1.52. Cytosorbents Corp has a 1-year low of $6.35 and a 1-year high of $14.95. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.52 and a current ratio of 3.70.
Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Tuesday, May 7th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. The business had revenue of $5.19 million during the quarter, compared to analysts’ expectations of $6.03 million. Cytosorbents had a negative return on equity of 103.90% and a negative net margin of 83.93%. On average, equities research analysts predict that Cytosorbents Corp will post -0.56 EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA acquired a new position in shares of Cytosorbents during the 1st quarter worth about $47,000. Stephens Inc. AR acquired a new position in shares of Cytosorbents during the 4th quarter worth about $81,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Cytosorbents by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,442 shares of the medical research company’s stock valued at $84,000 after purchasing an additional 8,155 shares during the period. Virtu Financial LLC acquired a new stake in shares of Cytosorbents in the 4th quarter valued at about $92,000. Finally, Menta Capital LLC acquired a new stake in shares of Cytosorbents in the 4th quarter valued at about $103,000. 27.19% of the stock is owned by institutional investors and hedge funds.
Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Further Reading: Capital gains and your 401(k) or IRA
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.